Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma

Cell Rep. 2022 Sep 27;40(13):111420. doi: 10.1016/j.celrep.2022.111420.

Abstract

Recurrence of solid tumors renders patients vulnerable to advanced, treatment-refractory disease state with mutational and oncogenic landscape distinctive from initial diagnosis. Improving outcomes for recurrent cancers requires a better understanding of cell populations that expand from the post-therapy, minimal residual disease (MRD) state. We profile barcoded tumor stem cell populations through therapy at tumor initiation, MRD, and recurrence in our therapy-adapted, patient-derived xenograft models of glioblastoma (GBM). Tumors show distinct patterns of recurrence in which clonal populations exhibit either a pre-existing fitness advantage or an equipotency fitness acquired through therapy. Characterization of the MRD state by single-cell and bulk RNA sequencing reveals a tumor-intrinsic immunomodulatory signature with prognostic significance at the transcriptomic level and in proteomic analysis of cerebrospinal fluid (CSF) collected from patients with GBM. Our results provide insight into the innate and therapy-driven dynamics of human GBM and the prognostic value of interrogating the MRD state in solid cancers.

Keywords: CP: Cancer; cellular barcoding; glioblastoma; glioblastoma stem cells; liquid biopsy; single-cell RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Neoplasms* / pathology
  • Glioblastoma* / genetics
  • Glioblastoma* / pathology
  • Humans
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm, Residual / genetics
  • Neoplastic Stem Cells / pathology
  • Proteomics

Grants and funding